SYKStryker Corporation
Stryker Corporation (SYK) sells surgical robotics, orthopaedic implants, and medical imaging systems — tools that turn human hands into precision machines. Its next catalyst is Oct 30, 2026 — Q3 2026 Earnings Release & Procedural Volume Update, which will test whether its core business can sustain the 18.4% revenue growth it posted in the last year. The event will also reveal how well its new TPX HD power tool and Pangea plating system are translating into real-world surgical demand .
- Stryker’s revenue hit $24.69B in 2026, with a net margin of 15.2% and free cash flow of $5.35B.
- Its debt-to-equity ratio is 0.15x, and it’s generating $3.76B in net income.
- The company’s leverage is low, but its cash flow is high — a sign of operational strength.
The schedule
- Fri30Oct
Q3 2026 financial results assessing the sustainability of the recent 9.4% revenue growth momentum and procedural volume trends leading into year-end.
- Thu12Nov
Finalized CMS payment updates for hospital outpatient services, which directly impact hospital budgets for Stryker's capital equipment purchases.
- Tue9Feb
Crucial Q4 print featuring initial FY27 earnings guidance, where management's conservatism often sets the tone for the coming fiscal year.
- Mon3May
First quarter results of FY27, focusing on capital equipment placement figures and early-year margin trends.
- Fri30Jul
Mid-year update providing an opportunity for management to raise full-year revenue and EPS guidance based on half-year execution.
Past
- Tue15Sep
Actual outcome: Bear · $273.23 at outcome
The Trump administration signaled stricter-than-expected Medicare reimbursement policies for orthopedic procedures and a reduction in hospital capital expenditure incentives. This directly threatened Stryker's near-term revenue outlook for both its high-margin implants and large capital equipment like the Mako robotic systems, triggering a sharp sell-off. While the market had anticipated some regulatory shifts, the severity of the proposed reimbursement cuts exceeded the modeled downside risks, catching investors off guard.
Market pricing of forthcoming shifts in healthcare regulatory policy under President Trump, focusing on procedural reimbursements and hospital capital expenditure incentives.
- Fri31Jul
Actual outcome: Bull · $337.03 at outcome
Stock rose 7.1% from event to outcome date, aligning with the bull trajectory.
- Mon11May
Actual outcome: Bear · $315.13 at outcome
Stryker reported Q1 2026 EPS of $2.21, exactly matching Wall Street estimates and providing no significant upside surprise. Without a clear fundamental breakout or major guidance update to justify its premium multiple, the stock remained flat. The market balanced these in-line results and ongoing fiduciary duty investigations, keeping shares well below the $342 bull target.
- Wed11Feb
Actual outcome: Mixed · $360.82 at outcome
Stryker reported Q4 2025 EPS of $2.21, exactly matching consensus estimates. The perfectly in-line earnings and lack of major surprises in the 2026 guidance led to a muted market reaction. As a result, the stock experienced a modest 1.8% gain, reflecting a balanced response to the predictable results.
